AR132159A1 - Anticuerpos anti-b7h3 y métodos de uso - Google Patents
Anticuerpos anti-b7h3 y métodos de usoInfo
- Publication number
- AR132159A1 AR132159A1 ARP240100660A ARP240100660A AR132159A1 AR 132159 A1 AR132159 A1 AR 132159A1 AR P240100660 A ARP240100660 A AR P240100660A AR P240100660 A ARP240100660 A AR P240100660A AR 132159 A1 AR132159 A1 AR 132159A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- antibody
- seq
- binding fragment
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente divulgación proporciona anticuerpos o fragmentos de unión a antígeno de los mismos que se unen a 4Ig-B7H3 humana. Reivindicación 1: Un anticuerpo o fragmento de unión a antígeno del mismo que se une específicamente a 4Ig-B7H3 humana, comprendiendo el anticuerpo o fragmento de unión a antígeno del mismo: (1) una región variable de la cadena pesada (VH) que comprende (a) una HCDR1 (Región Determinante de la Complementariedad de la Cadena Pesada 1) de SEQ ID Nº 7, (b) una HCDR2 de SEQ ID Nº 8, y (c) una HCDR3 de SEQ ID Nº 9; o (2) una región variable de la cadena pesada que comprende (a) una HCDR1 de SEQ ID Nº 12, (b) una HCDR2 de SEQ ID Nº 13, y (c) una HCDR3 de SEQ ID Nº 14. Reivindicación 7: Un anticuerpo multiespecífico o fragmento de unión a antígeno del mismo que comprende al menos un primer dominio de unión a antígeno que se une específicamente a un primer antígeno tumoral humano (TAA), en donde el primer TAA es 4Ig-B7H3 humana y el primer dominio de unión a antígeno comprende el anticuerpo o fragmento de unión a antígeno del mismo de una cualquiera de las reivindicaciones anteriores; y al menos un segundo dominio de unión a antígeno que se une específicamente a un segundo TAA humano. Reivindicación 15: Una composición farmacéutica que comprende el anticuerpo o fragmento de unión a antígeno del mismo de una cualquiera de las reivindicaciones anteriores y un portador farmacéuticamente aceptable. Reivindicación 16: Un ácido nucleico aislado que codifica el anticuerpo o fragmento de unión a antígeno del mismo de una cualquiera de las reivindicaciones 1 a 14. Reivindicación 17: Un vector que comprende el ácido nucleico de la reivindicación 16. Reivindicación 18: Una célula huésped que comprende el ácido nucleico de la reivindicación 16 o el vector de la reivindicación 17. Reivindicación 19: Un proceso para producir un anticuerpo o fragmento de unión a antígeno del mismo que comprende cultivar la célula huésped de la reivindicación 18 y recuperar el anticuerpo o fragmento de anticuerpo del cultivo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2023082099 | 2023-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132159A1 true AR132159A1 (es) | 2025-05-28 |
Family
ID=92840909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100660A AR132159A1 (es) | 2023-03-17 | 2024-03-18 | Anticuerpos anti-b7h3 y métodos de uso |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4680643A1 (es) |
| KR (1) | KR20250160360A (es) |
| CN (1) | CN120958028A (es) |
| AR (1) | AR132159A1 (es) |
| AU (1) | AU2024237990A1 (es) |
| CO (1) | CO2025013921A2 (es) |
| IL (1) | IL323120A (es) |
| MX (1) | MX2025010929A (es) |
| TW (1) | TW202438527A (es) |
| WO (1) | WO2024193450A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110642948B (zh) * | 2019-10-09 | 2021-06-29 | 达石药业(广东)有限公司 | B7-h3纳米抗体、其制备方法及用途 |
| AU2020370125A1 (en) * | 2019-10-22 | 2022-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity nanobodies targeting B7H3 (CD276) for treating multiple solid tumors |
| WO2021097800A1 (en) * | 2019-11-22 | 2021-05-27 | Abl Bio Inc. | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof |
| CA3182602A1 (en) * | 2020-06-26 | 2021-12-30 | Taekyo PARK | Antibody-drug conjugates comprising anti-b7-h3 antibodies |
| US12133890B2 (en) * | 2021-07-01 | 2024-11-05 | Ningbo T-Maximum Biopharmaceuticals Co., Ltd. | Antigen-binding polypeptide targeting B7H3 and application thereof |
-
2024
- 2024-03-15 KR KR1020257034260A patent/KR20250160360A/ko active Pending
- 2024-03-15 CN CN202480018824.3A patent/CN120958028A/zh active Pending
- 2024-03-15 WO PCT/CN2024/081840 patent/WO2024193450A1/en not_active Ceased
- 2024-03-15 EP EP24774016.0A patent/EP4680643A1/en active Pending
- 2024-03-15 TW TW113109688A patent/TW202438527A/zh unknown
- 2024-03-15 AU AU2024237990A patent/AU2024237990A1/en active Pending
- 2024-03-18 AR ARP240100660A patent/AR132159A1/es unknown
-
2025
- 2025-09-02 IL IL323120A patent/IL323120A/en unknown
- 2025-09-15 MX MX2025010929A patent/MX2025010929A/es unknown
- 2025-10-08 CO CONC2025/0013921A patent/CO2025013921A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL323120A (en) | 2025-11-01 |
| MX2025010929A (es) | 2025-10-01 |
| CN120958028A (zh) | 2025-11-14 |
| CO2025013921A2 (es) | 2025-10-20 |
| AU2024237990A1 (en) | 2025-09-25 |
| TW202438527A (zh) | 2024-10-01 |
| WO2024193450A9 (en) | 2025-10-09 |
| KR20250160360A (ko) | 2025-11-12 |
| WO2024193450A1 (en) | 2024-09-26 |
| EP4680643A1 (en) | 2026-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110755A1 (es) | Anticuerpos dirigidos a hueso | |
| PE20240363A1 (es) | Anticuerpos anti-ccr8 y usos de los mismos | |
| IL273841B1 (en) | Antibodies targeting cd137 and methods of use thereof | |
| AR123083A1 (es) | Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos | |
| JP2020534830A5 (es) | ||
| AR123997A1 (es) | ANTICUERPOS NEUTRALIZANTES CONTRA EL SARS-CoV-2 | |
| AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
| PE20220763A1 (es) | Materiales y metodos para modular la inmunidad mediada por celulas t | |
| CO2018001256A2 (es) | Anticuerpos anti-cd154 y métodos para producir los mismos | |
| JP2017521054A5 (es) | ||
| PE20230616A1 (es) | Anticuerpos que se unen a cd3 y folr1 | |
| AR127271A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos | |
| AR123537A1 (es) | Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca | |
| AR129991A1 (es) | Anticuerpos que se unen a la pad4 humana y usos de los mismos | |
| AR129935A1 (es) | Anticuerpo, enlazadores, carga activa, conjugados y aplicaciones de los mismos | |
| AR110967A1 (es) | Anticuerpos miméticos fgf21 y su uso | |
| AR125488A1 (es) | Proteínas de unión biespecíficas de pd-1 y de tigit, y usos de las mismas | |
| PE20240589A1 (es) | ANTICUERPOS CD1a Y SU USO | |
| AR131528A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| AR125074A1 (es) | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso | |
| AR132159A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| AR127273A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y her2 y usos de los mismos | |
| AR132064A1 (es) | Anticuerpos anti-cldn6 y métodos de uso | |
| AR130130A1 (es) | Proteínas de unión al receptor de transferrina para tratar tumores cerebrales | |
| AR132043A1 (es) | Anticuerpos muc1 y métodos de uso |